Health Tech Capitol | Exact Sciences’ stock soars after it says Cologuard tests near 1 million for 2018
16522
post-template-default,single,single-post,postid-16522,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Exact Sciences’ stock soars after it says Cologuard tests near 1 million for 2018

08 Jan Exact Sciences’ stock soars after it says Cologuard tests near 1 million for 2018

Posted at 11:17h in Uncategorized by
0 Likes

Exact Sciences Corp. stock climbed nearly 15 percent Monday after the Madison cancer diagnostics company offered preliminary results for the last three months of 2018 that topped projections, showing more than 930,000 people used Exact’s Cologuard home test kit for colorectal cancer last year.

Revenue for the October-December quarter will likely come in at $142.5 million to $143.5 million, the company said. That’s 64 percent higher than the 2017 fourth quarter, when the company took in $87.4 million.

For all of 2018, Exact said it projects revenue of $454 million to $455 million — a 71 percent increase over 2017.

Read more at the Wisconsin State Journal

 

No Comments

Sorry, the comment form is closed at this time.